These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18497527)

  • 21. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.
    Amano S; Rohan R; Kuroki M; Tolentino M; Adamis AP
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):18-22. PubMed ID: 9430540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emodin suppression of ocular surface inflammatory reaction.
    Kitano A; Saika S; Yamanaka O; Ikeda K; Okada Y; Shirai K; Reinach PS
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5013-22. PubMed ID: 17962452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
    Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions.
    Premanand C; Rema M; Sameer MZ; Sujatha M; Balasubramanyam M
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2179-84. PubMed ID: 16639030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2‑mediated STAT3/PI3K/Akt signaling pathway.
    Shen M; Zhou XZ; Ye L; Yuan Q; Shi C; Zhu PW; Jiang N; Ma MY; Yang QC; Shao Y
    Int J Mol Med; 2018 Aug; 42(2):769-778. PubMed ID: 29717775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Curcumin inhibits the expression of vascular endothelial growth factor and androgen-independent prostate cancer cell line PC-3 in vitro].
    Deng G; Yu JH; Ye ZQ; Hu ZQ
    Zhonghua Nan Ke Xue; 2008 Feb; 14(2):116-21. PubMed ID: 18390174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of trehalose on VEGF-stimulated angiogenesis and myofibroblast proliferation: implications for glaucoma filtration surgery.
    Takeuchi K; Nakazawa M; Ebina Y
    Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):6987-93. PubMed ID: 21778273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells.
    Kumar A; D'Souza SS; Nagaraj SR; Gaonkar SL; Salimath BP; Rai KM
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1221-33. PubMed ID: 19370348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration.
    Lu P; Li L; Mukaida N; Zhang X
    Cornea; 2007 Feb; 26(2):199-206. PubMed ID: 17251813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization.
    Mwaikambo BR; Sennlaub F; Ong H; Chemtob S; Hardy P
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4356-64. PubMed ID: 17003426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.
    Chen P; Yin H; Wang Y; Mi J; He W; Xie L; Wang Y
    Mol Vis; 2010 Feb; 16():310-9. PubMed ID: 20208988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.
    Han YS; Lee JE; Jung JW; Lee JS
    Graefes Arch Clin Exp Ophthalmol; 2009 Apr; 247(4):541-8. PubMed ID: 18953554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.
    Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH
    Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of chemical cautery-induced corneal neovascularization by topical pigment epithelium-derived factor eyedrops.
    Jin J; Ma JX; Guan M; Yao K
    Cornea; 2010 Sep; 29(9):1055-61. PubMed ID: 20539216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Inhibition of rat corneal neovascularization by inhibitor of nuclear factor-kappaB].
    Wang Y; Zhang MC; Hu YZ; Yu CT
    Zhonghua Yan Ke Za Zhi; 2005 Dec; 41(12):1124-8. PubMed ID: 16409768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin nanoparticles inhibit corneal neovascularization.
    Pradhan N; Guha R; Chowdhury S; Nandi S; Konar A; Hazra S
    J Mol Med (Berl); 2015 Oct; 93(10):1095-106. PubMed ID: 25877858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenic effects of catalpol on rat corneal neovascularization.
    Han Y; Shen M; Tang LY; Tan G; Yang QC; Ye L; Ye LH; Jiang N; Gao GP; Shao Y
    Mol Med Rep; 2018 Feb; 17(2):2187-2194. PubMed ID: 29207076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis.
    Hahm ER; Gho YS; Park S; Park C; Kim KW; Yang CH
    Biochem Biophys Res Commun; 2004 Aug; 321(2):337-44. PubMed ID: 15358181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of liver cirrhosis in rats by curcumin.
    Bruck R; Ashkenazi M; Weiss S; Goldiner I; Shapiro H; Aeed H; Genina O; Helpern Z; Pines M
    Liver Int; 2007 Apr; 27(3):373-83. PubMed ID: 17355460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-inflammatory activity for optimization of therapy of inflammatory bowel disease.
    Yadav VR; Suresh S; Devi K; Yadav S
    J Pharm Pharmacol; 2009 Mar; 61(3):311-21. PubMed ID: 19222903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.